TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients
TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More
GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate ... Read More